Longifolioside A inhibits TLR4-mediated inflammatory responses by blocking PKCδ activation in LPS-stimulated THP-1 macrophages. (July 2020)
- Record Type:
- Journal Article
- Title:
- Longifolioside A inhibits TLR4-mediated inflammatory responses by blocking PKCδ activation in LPS-stimulated THP-1 macrophages. (July 2020)
- Main Title:
- Longifolioside A inhibits TLR4-mediated inflammatory responses by blocking PKCδ activation in LPS-stimulated THP-1 macrophages
- Authors:
- Lee, Su Ui
Oh, Eun Sol
Ryu, Hyung Won
Kim, Mun-Ock
Kang, Myung-Ji
Song, Yu Na
Lee, Ro Woon
Kim, Doo-Young
Ro, Hyunju
Jung, Sunin
Hong, Sung-Tae
Oh, Sei-Ryang - Abstract:
- Abstract: Longifolioside A is an iridoid glucoside compound isolated from Pseudolysimachion rotundum var . subintegrum, which has been used in traditional herbal medicines to treat respiratory inflammatory diseases. Logifolioside A is a potent antioxidant; however, its underlying pharmacological mechanisms of action in inflammatory diseases are unknown. Here, we investigated the inhibitory effects of longifolioside A in lipopolysaccharide (LPS)-stimulated toll-like receptor 4 (TLR4) signal transduction systems using human THP-1 macrophages and HEK293 cells stably expressing human TLR4 protein (293/HA-hTLR4). Longifolioside A significantly reduced the release of inflammatory cytokines such as interleukin (IL)-6, -8, and tumor necrosis factor (TNF)-α in LPS-stimulated THP-1 macrophages. Furthermore, longifolioside A inhibited the expression of inflammatory mediator genes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 that produce nitric oxide (NO) and prostaglandin E2 (PGE2), respectively. Longifolioside A suppressed the phosphorylation of PKCδ, IRAK4, IKKα/β, IκBα, and mitogen-activated protein (MAP) kinases (ERK 1/2 and JNK, but not p38), thereby inactivating the nuclear localization of NF-κB and AP-1, and thus decreasing the expression of inflammatory response genes. Notably, longifolioside A disrupted the interaction between human TLR4 and the TIR domain-containing adaptor protein (TIRAP), an early step during TLR4 activation, thereby reducingAbstract: Longifolioside A is an iridoid glucoside compound isolated from Pseudolysimachion rotundum var . subintegrum, which has been used in traditional herbal medicines to treat respiratory inflammatory diseases. Logifolioside A is a potent antioxidant; however, its underlying pharmacological mechanisms of action in inflammatory diseases are unknown. Here, we investigated the inhibitory effects of longifolioside A in lipopolysaccharide (LPS)-stimulated toll-like receptor 4 (TLR4) signal transduction systems using human THP-1 macrophages and HEK293 cells stably expressing human TLR4 protein (293/HA-hTLR4). Longifolioside A significantly reduced the release of inflammatory cytokines such as interleukin (IL)-6, -8, and tumor necrosis factor (TNF)-α in LPS-stimulated THP-1 macrophages. Furthermore, longifolioside A inhibited the expression of inflammatory mediator genes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 that produce nitric oxide (NO) and prostaglandin E2 (PGE2), respectively. Longifolioside A suppressed the phosphorylation of PKCδ, IRAK4, IKKα/β, IκBα, and mitogen-activated protein (MAP) kinases (ERK 1/2 and JNK, but not p38), thereby inactivating the nuclear localization of NF-κB and AP-1, and thus decreasing the expression of inflammatory response genes. Notably, longifolioside A disrupted the interaction between human TLR4 and the TIR domain-containing adaptor protein (TIRAP), an early step during TLR4 activation, thereby reducing IL-8 secretion in 293/HA-hTLR4 cells. This inhibitory effect was comparable to that of TAK-242 (a TLR4 inhibitor, or resatorvid). Our results indicate that longifolioside A prevents inflammatory response by suppressing TLR4 activation required for NF-κB and AP-1 activation. … (more)
- Is Part Of:
- Cytokine. Volume 131(2020)
- Journal:
- Cytokine
- Issue:
- Volume 131(2020)
- Issue Display:
- Volume 131, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 131
- Issue:
- 2020
- Issue Sort Value:
- 2020-0131-2020-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-07
- Subjects:
- Longifolioside A -- Inflammation -- Lipopolysaccharides -- Toll-like receptor 4 -- Toll/interleukin-1 receptor domain-containing adapter protein
e.g. exempli gratia -- ELISA enzyme-linked immunosorbent assay -- eNOS endothelial NOS -- ERK 1/2 extracellular signal-regulated kinases 1/2 -- iNOS inducible nitric oxide synthase -- IRAK Interleukin-1 receptor-associated kinases -- JNK c-Jun N-terminal kinase -- MYD88 Myeloid differentiation primary response gene 88 -- NF-κB nuclear factor-kappaB -- nNOS neuronal nitric oxide synthase -- TIRAP Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein -- TLR4 Toll-like receptor 4
Cytokines -- Periodicals
571.844 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10434666 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.cyto.2020.155116 ↗
- Languages:
- English
- ISSNs:
- 1043-4666
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3506.778000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13448.xml